1 recruiting, 1 suspended. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Suspended 1 |
| Phase 2 | 2 | Recruiting 1, Suspended 1 |
Follow Relapsed or Refractory Lymphoma Including ENKL: new trials by email Literature Review of Relapsed or Refractory Lymphoma Including ENKL trials Research Report on Relapsed or Refractory Lymphoma Including ENKL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL tislezumab, golidocitinib, Selinexor - Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Recruiting | Fudan University | 68 | 2025-05-26 | 2025-05-30 |
Recurrence (2) · Epstein-Barr Virus Infections (1) · Immunoblastic Lymphadenopathy (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, T-Cell (1) · Lymphadenopathy (1) · Lymphatic Diseases (1)
brincidofovir (1) · selinexor (1)
Fudan University (1) · SymBio Pharmaceuticals (1)
China (2) · Japan (1) · Singapore (1)
PMID 28188133, PMID 34702811, PMID 37616529, PMID 38092009, PMID 38900877